Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖

基本信息

  • 批准号:
    8918454
  • 负责人:
  • 金额:
    $ 112.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Clinical Oncology Research Career Development Program (CDP) at the University of California, Davis (UC Davis) will train junior faculty scholars to be independent, patient-oriented cancer researchers. The scholars will conduct translational research to develop laboratory-driven clinical trials designed to optimize novel therapeutic approaches based on the underlying molecular profiles of individual patient tumors or tumor types. The CDP will produce new faculty members from diverse backgrounds who are skilled leaders in team science. UC Davis is well-positioned to train the next generation of clinician scientists in oncology because of its outstanding patient care; long-standing and well-funded infrastructure in clinical-translational investigation (including cancer clinical trials), including our NCI-designated Cancer Center and NCRR-funded Clinical and Translational Science Center (CTSC); experience in laboratory-clinical correlative science; and established inter- and intra-institution consortia, among other resources. Upon successful completion of a three-year, salary-supported core curriculum, Scholars will receive a UC Davis Cancer Center Certificate in Clinical Cancer Research. We will combine key didactic, research, and career development components to produce independent and productive clinical oncology researchers over the course of a three-year program. We will accomplish our goals through the following specific aims: 1) 1) Offer a mentored, competency-based didactic curriculum so Scholars can integrate basic, translational, and clinical science knowledge to discover and/or evaluate more effective treatments for cancer that improve patient outcome; 2) Oversee individualized patient oriented research projects (investigator-initiated clinical trials) customized to the interests and needs of each CDP Scholar; and 3) Provide oversight of CDP Scholar training to ensure the progressive development of a high-quality "end-product": a fully competent interdisciplinary-oriented clinician scientist who can successfully conduct translational cancer clinical trials with investigational new agents or devices. The curriculum for the CDP will be guided by two research tracks in Basic/Translational and Clinical science. Each trainee will gain appropriate, integrated didactic and "hands-on" mentored research training following a plan supervised by two senior, independently funded faculty members (one Basic/Translational mentor and one Clinical mentor) to be able to successfully tackle research questions in one of these tracks. We have incorporated unique venues for training in team science and interdisciplinary research into the curriculum in order to take advantage of the strengths of other training programs at UC Davis, particularly those housed in the CTSC. Our overall goal is to develop successful, independent clinical cancer researchers who will be able to work in teams to develop and test new cancer treatments based upon their understanding of the complex mechanisms underlying cancer biology and how they manifest disease in individual patients as well as in broad populations. Thus, we need to make the clinician well-versed in the language of the laboratory scientist and vice-versa. The long-term success of our multidisciplinary approach to understanding and developing targeted treatments for oncologic disease critically depends upon the training of a new generation of multidisciplinary researchers who possess ideas and skills that go far beyond their initial disciplinary boundaries.
描述(由申请人提供):加州大学戴维斯分校 (UC Davis) 的临床肿瘤学研究职业发展计划 (CDP) 将培训初级教师学者成为独立的、以患者为导向的癌症研究人员。学者们将进行转化研究,开发实验室驱动的临床试验,旨在根据个体患者肿瘤或肿瘤类型的基本分子谱优化新的治疗方法。 CDP 将培养来自不同背景的新教师,他们是团队科学领域的熟练领导者。加州大学戴维斯分校因其出色的患者护理而处于有利地位,可以培养下一代肿瘤学临床科学家;临床转化研究(包括癌症临床试验)方面拥有长期且资金充足的基础设施,包括我们 NCI 指定的癌症中心和 NCRR 资助的临床和转化科学中心 (CTSC);实验室临床相关科学经验;除其他资源外,还建立了机构间和机构内联盟。成功完成为期三年的带薪核心课程后,学者将获得加州大学戴维斯分校癌症中心临床癌症研究证书。我们将在为期三年的计划中结合关键的教学、研究和职业发展组成部分,培养独立且富有成效的临床肿瘤学研究人员。我们将通过以下具体目标来实现我们的目标:1) 1) 提供有指导的、基于能力的教学课程,以便学者能够整合基础、转化和临床科学知识,以发现和/或评估更有效的癌症治疗方法,从而改善患者的健康状况结果; 2) 监督根据每位 CDP 学者的兴趣和需求定制的个性化患者导向研究项目(研究者发起的临床试验); 3) 对 CDP 学者培训进行监督,以确保高质量“最终产品”的逐步开发:一位完全有能力的跨学科临床科学家,能够使用研究性新制剂或设备成功进行转化癌症临床试验。 CDP 的课程将以基础/转化和临床科学的两个研究方向为指导。每位学员将按照由两名独立资助的高级教员(一名基础/转化导师和一名临床导师)监督的计划,获得适当的、综合的教学和“实践”指导的研究培训,以便能够成功地解决研究问题这些曲目。我们将独特的团队科学和跨学科研究培训场所纳入课程中,以便利用加州大学戴维斯分校其他培训项目的优势,特别是 CTSC 中的培训项目。我们的总体目标是培养成功的、独立的临床癌症研究人员,他们将能够基于对癌症生物学的复杂机制以及它们如何在个体患者和个体中表现疾病的理解,以团队的方式开发和测试新的癌症治疗方法。广大人群。因此,我们需要让临床医生精通实验室科学家的语言,反之亦然。我们理解和开发肿瘤疾病靶向治疗的多学科方法的长期成功关键取决于对新一代多学科研究人员的培训,他们拥有远远超出其最初学科界限的想法和技能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PRIMO N. LARA其他文献

PRIMO N. LARA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PRIMO N. LARA', 18)}}的其他基金

Phase I Molecular and Clinical Pharmacodynamic Trials ETCTN
I 期分子和临床药效试验 ETCTN
  • 批准号:
    9095678
  • 财政年份:
    2014
  • 资助金额:
    $ 112.99万
  • 项目类别:
A Correlative Biomarker Analysis for A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory NHL
来那度胺和博纳吐单抗联合治疗复发或难治性 NHL 患者的 I 期试验的相关生物标志物分析
  • 批准号:
    10192396
  • 财政年份:
    2014
  • 资助金额:
    $ 112.99万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10681247
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    9336795
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10429982
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8302192
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8090131
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    8518259
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
加州大学戴维斯分校 Paul Calabresi K12 临床肿瘤学研究职业发展计划
  • 批准号:
    10195476
  • 财政年份:
    2011
  • 资助金额:
    $ 112.99万
  • 项目类别:
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis
加州大学戴维斯分校临床肿瘤学 (K12) Paul Calabresi 职业发展奖
  • 批准号:
    10018465
  • 财政年份:
    2009
  • 资助金额:
    $ 112.99万
  • 项目类别:

相似海外基金

Research Education
研究教育
  • 批准号:
    10762294
  • 财政年份:
    2023
  • 资助金额:
    $ 112.99万
  • 项目类别:
Career Enhancement Program
职业提升计划
  • 批准号:
    10708580
  • 财政年份:
    2023
  • 资助金额:
    $ 112.99万
  • 项目类别:
Core 2: Research Education
核心2:研究教育
  • 批准号:
    10762164
  • 财政年份:
    2023
  • 资助金额:
    $ 112.99万
  • 项目类别:
Washington University SPORE in Pancreatic Cancer
华盛顿大学 SPORE 在胰腺癌中的应用
  • 批准号:
    10708572
  • 财政年份:
    2023
  • 资助金额:
    $ 112.99万
  • 项目类别:
Cancer Research Training and Education Coordination
癌症研究培训和教育协调
  • 批准号:
    10625752
  • 财政年份:
    2023
  • 资助金额:
    $ 112.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了